Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance

Journal of Clinical Psychiatry

Volumn 66, Issue 10, 2005, Pages 1289-1297

  Shelton, Richard C ^a   Williamson, Douglas J ^b   Corya, Sara A ^b   Sanger, Todd M ^b   Van Campen, Luann E ^b   Case, Michael ^b   Briggs, Susan D ^b   Tollefson, Gary D ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; NORTRIPTYLINE; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 27544509056     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1012     Document Type: Article

References (30)

1. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996;19:371-386
2. Fawcett J. Progress in treatment-resistant depression and treatment-refractory depression: we still have a long way to go. Psychiatr Ann 1994;24:214-216
3. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(6, suppl):39-47
4. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
5. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-29
6. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 1998;59(suppl 5):5-12
7. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91
8. Lambert G, Johansson M, Agren H, et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000;57:787-793
9. Maes M, De Meester I, Scharpe S, et al. Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta Psychiatr Scand 1996;93:1-8
10. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-262
11. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
13. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-259
14. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)2E New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
17. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
19. US Food and Drug Administration. COSTART: The Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 1995
20. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
21. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
22. Munetz MR, Benjamin S. How to evaluate patients using the abnormal involuntary movement scale. Hosp Community Psychiatry 1988;39:1172-1177
23. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
24. Dubé S, Paul S, Sanger TM, et al. Olanzapine-fluoxetine combination in treatment-resistant depression [abstract]. Eur Psychiatry 2002;17:98
25. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):36-47
26. Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989;28:1-9
27. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003;64:1349-1356
28. Symbyax [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2003
29. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
30. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-373